Indeed, sema3F and sema3B have been characterized as bona fide tumor suppressors of lung cancer [98,99,100,101], and sema3A has been found to function as an endogenous angiogenesis inhibitor that is down-regulated during tumor progression [88]. This evidence concerns the gene SEMA3B and lung cancer.